Prognostic factors of survival in patients treated with nab-paclitaxel plus gemcitabine regimen for advanced or metastatic pancreatic cancer: A single institutional experience

作者：Giovanni Lo Re, Davide Adriano Santeufemia, Luisa Foltran, Ettore Bidoli, S.M.M. Basso, Franco Lumachi · 发表于：Oncotarget · 年份：2015 · DOI：10.18632/oncotarget.3143 · 被引用次数：15 · 研究领域：Pancreatic and Hepatic Oncology Research、Renal cell carcinoma treatment、Neuroendocrine Tumor Research Advances

// Giovanni Lo Re 1 , Davide A. Santeufemia 1 , Luisa Foltran 1 , Ettore Bidoli 2 , Stefano M.M. Basso 3 , Franco Lumachi 4 1 Oncology Unit, S. Maria degli Angeli Hospital, 33170 Pordenone, Italy 2 Epidemiology Unit, Centro di Riferimento Oncologico (CRO), 33081 Aviano, Pordenone, Italy 3 Surgery 2, S. Maria degli Angeli Hospital, 33170 Pordenone, Italy 4 Department of Surgery, Oncology and Gastroenterology, University of Padua, School of Medicine, 35128 Padova, Italy Correspondence to: Giovanni Lo Re, e-mail: giovanni.lore@hotmail.it Keywords: advanced pancreatic cancer, metastasis, nab-paclitaxel, gemcitabine, prognostic factors Received: December 11, 2014 Accepted: January 12, 2015 Published: March 10, 2015 ABSTRACT Purpose The objectives of this study were to evaluate the effectiveness of nab-paclitaxel plus gemcitabine (NAB-P/GEM) regimen in an unselected population of patients with advanced inoperable or metastatic pancreatic cancer (PC), and to identify the prognostic factors influencing overall survival (OS). Experimental design Patients with age < 85 years, ECOG-performance status (PS) < 3, and adequate renal, hepatic and hematologic function were eligible. NAB-P (125 mg/m2) and GEM (1000 mg/m2) day 1,8,15 every 4 weeks were employed for 3–6 cycles or until highest response. Results Overall, 147 cycles (median 4, range 1–11 cycles) were administered on thirty-seven consecutive patients (median 66 years old, range 40–82) treated. The median overall progression-free su...